CG Oncology Stock Quote CGON - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

41.00

Bid

37.82

Ask

47.00

Volume

819,590

36.495 Day's Range 41.21

28.55 52 Week Range 50.23

Market Cap

1.982B

Previous Close

36.20

Open

36.93

Last Trade

182

(formt)

Last Trade Time

Financial Volume

$ 33,041,511

VWAP

40.3147

Average Volume (3m)

542,333

Shares Outstanding

48,330,000

Dividend Yield

PE Ratio

-29.23

Earnings Per Share (EPS)

-1.4

Revenue

204k

Net Profit

-67.8M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

cgoncology.com

Headquarters

Dover, Delaware, USA

Founded

1970

CG Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGON. The last closing price for CG Oncology was $36.20. Over the last year, CG Oncology shares have traded in a share price range of $ 28.55 to $ 50.23.

CG Oncology currently has 48,330,000 shares outstanding. The market capitalization of CG Oncology is $1.98 billion. CG Oncology has a price to earnings ratio (PE ratio) of -29.23.

Overall Flow

Bearish

Net Premium

-27k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology’s earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) - - Primary...

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	5.99	17.1093973151	35.01	41.21	33.39	274811	35.53991077	CS
4	-2.82	-6.43541761753	43.82	44.26	33.39	327414	38.15552152	CS
12	3	7.89473684211	38	50.23	32.65	542333	39.92439458	CS
26	12	41.3793103448	29	50.23	28.55	656352	39.13741999	CS
52	12	41.3793103448	29	50.23	28.55	656352	39.13741999	CS
156	12	41.3793103448	29	50.23	28.55	656352	39.13741999	CS
260	12	41.3793103448	29	50.23	28.55	656352	39.13741999	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M